Analyst Research Report Snapshot

Title:

NEUROSEARCH - MERMAIHD ANALYSIS SNAFU

Price:

$10.00

Provider:

Edison Investment Research

Date:

30 Apr 2010

Pages:

8

Type:

AcrobatPDF

Companies referenced:

NEUR.CO

Available for Immediate Download
Summary:

An oversight in the analysis plan for the MermaiHD study of Huntexil for Huntington’s disease has resulted in the study being deemed not to have met its high, pre-specified level of significance (p<0.025) on its primary endpoint. The statistical plan did not specify the use of a clinically-appropriate adjustment for differences in baseline characteristics and NeuroSearch has had to restate the outcome before this adjustment. This introduces a minor regulatory concern, although, in our view, it could only affect Huntexil’s approvability if the HART study (due in Q3) is negative. FOR MORE INFORMATION ON THE ATTACHED RESEARCH PLEASE CALL 020 3077 5700, EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.